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Abstract Aberrant expression of microRNAs (miRNAs),
a class of small non-coding regulatory RNAs, has been
implicated in the development and progression of high-
grade gliomas. However, the precise mechanistic role of
many miRNAs in this disease remains unclear. Here, we
investigate the functional role of miR-331-3p in glioblas-
toma multiforme (GBM). We found that miR-331-3p
expression in GBM cell lines is significantly lower than in
normal brain, and that transient overexpression of miR-
331-3p inhibits GBM cell line proliferation and clonogenic
growth, suggesting a possible tumor suppressor role for
miR-331-3p in this system. Bioinformatics analysis iden-
tified neuropilin-2 (NRP-2) as a putative target of miR-
331-3p. Using transfection studies, we validated NRP-2
mRNA as a target of miR-331-3p in GBM cell lines, and
show that NRP-2 expression is regulated by miR-331-3p.
RNA interference (RNAi) to inhibit NRP-2 expression
in vitro decreased the growth and clonogenic growth of
GBM cell lines, providing further support for an oncogenic
role for NRP-2 in high-grade gliomas. We also show that
miR-331-3p inhibits GBM cell migration, an effect due in
part to reduced NRP-2 expression. Finally, we identified a
significant inverse correlation between miR-331-3p and
NRP-2 expression in The Cancer Genome Atlas GBM
cohort of 491 patients. Together, our results suggest that a
loss of miR-331-3p expression contributes to GBM
development and progression, at least in part via upregu-
lating NRP-2 expression and increasing cell proliferation
and clonogenic growth.
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Introduction
Glioblastoma multiforme (GBM) is the most common and
lethal adult malignant brain tumor [1]. Despite advances in
the standard therapy for GBM, which involves surgery
followed by the combination of radiotherapy and tem-
ozolomide chemotherapy, tumor recurrence and treatment
resistance are common and the median survival time of
patients is only approximately 15 months [2]. Hence there
is a pressing need to develop new approaches to treat this
disease, and in recent years significant progress has been
made in understanding the molecular biology of GBM,
including the identification of aberrations in key cell sig-
naling pathways that promote GBM tumorigenesis [2].
Furthermore, it has been shown that microRNAs (miR-
NAs)—short non-coding RNAs that repress gene expres-
sion by binding to specific target mRNAs—have altered
expression in a variety of cancers, including GBM
(reviewed in [3]), where they may act as oncogenes or
tumor suppressor genes. For example, miR-21 is overex-
pressed in GBM and promotes tumor cell growth, survival
and invasion [4–6], and inhibition of miR-21 sensitizes
GBM cells to temozolomide chemotherapy [7]. Reduced
expression of tumor suppressor miRNAs, including miR-7,
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miR-34a, and the let-7 miRNA family promotes oncogenic
signaling in GBM [8–10]. These findings and others sug-
gest not only the potential for miRNAs to serve as prog-
nostic and diagnostic molecules in GBM, but also that the
delivery of inhibitors of oncogenic miRNAs and/or
replacement therapy using mimics of tumor suppressor
miRNAs represents a novel strategy to treat GBM
(reviewed in [11]).
Previously, we and others identified miR-331-3p as a
tumor suppressor miRNA that is downregulated in prostate
cancer, where it mediates ErbB-2 expression and PI3K/Akt
signaling [12, 13], as well as expression of deoxyhypusine
hydroxylase (DOHH), an enzyme that activates eukaryotic
translation initiation factor (eIF5A) and regulates cell
growth [14]. Following a report that miR-331-3p expres-
sion was reduced in a panel of central nervous system
tumor cell lines [6], we investigated the expression and
function of miR-331-3p in GBM. In this paper, we show
that miR-331-3p expression is decreased in a panel of
GBM cell lines relative to normal brain tissue and that
miR-331-3p inhibits the growth and clonogenicity of GBM
cell lines in vitro. Furthermore, we show that miR-331-3p
inhibits expression of neuropilin-2 (NRP-2), a receptor
implicated in neuronal development, axon guidance and
tumorigenesis, and that NRP-2 promotes the growth and
clonogenicity of GBM cell lines in vitro. Transfection with
miR-331-3p also suppresses GBM cell migration in vitro,
in part by its inhibition of NRP-2 expression. Finally,
analysis of miRNA and mRNA expression data from The
Cancer Genome Atlas (TCGA) GBM cohort shows an
inverse correlation between miR-331-3p and NRP-2 levels
in clinical GBM samples. Our findings suggest that miR-
331-3p may have prognostic or therapeutic utility in the
management of GBM.
Experimental procedures
Cell culture, plasmid DNA, miRNA precursor
and siRNA molecules
U-251 MG, U-373 MG and U-87 MG glioblastoma cell
lines were obtained from the American Type Culture
Collection (ATCC) and cultured at 37 C in 5 % CO2 with
RPMI-1640 supplemented with 10 % fetal bovine serum.
The NRP-2 30-UTR and negative control reporter clones
were obtained from Gencopoeia (NRP-2 reporter; Cat#
HmiT021592-MT01: Negative control reporter; Cat #
CmiT000001-MT01). All plasmids were verified by DNA
sequencing prior to use. Synthetic miRNA precursor mol-
ecules corresponding to human miR-331-3p (pre-miR
miRNA Precursor Product ID: PM10881 and negative
control miRNA (miR-NC; pre-miR miRNA precursor
negative control #1, Product ID: AM17110) were obtained
from Ambion. Synthetic siRNA precursor molecules cor-
responding to human NRP-2 (Silencer Select si-NRP-2;
Cat #4390824 ID:16840) and siRNA negative control
molecules (Silencer Select si-NC; Cat #4390843) were
obtained from Ambion.
RNA extraction, reverse transcription and quantitative
polymerase chain reaction (RT-qPCR)
Total normal brain RNA was obtained from Ambion (Cat
#AM7962) and used as a reference control sample. Total
RNA from GBM cell lines was extracted using Qiazol
reagent (Qiagen). For miRNA detection, quantitative
Taqman qRT-PCR was performed using TaqMan miRNA
assays (Life Technologies) for hsa-miR-331-3p and
RNU6B small nuclear RNA (Life Technologies; Assay IDs
000545 and 001093), with 10 ng total RNA. Reactions
were carried using a Rotor-Gene 6000 thermocycler (Qia-
gen). Expression of mature miR-331-3p relative to RNU6B
small nuclear RNA (snRNA) was determined using the
2-DDCt method [15]. Statistical analysis of RT-qPCR data
was performed using GenEx software (MultiD).
Transfection of siRNA/miRNA precursor molecules
and reporter gene assays
GBM cells were seeded into 12 well or 10 cm dishes and
transfected with siRNA or miRNA precursor molecules at a
final concentration of 5 nM and 1–30 nM, respectively.
Briefly, GBM cells were transfected with siRNA to NRP-2
(NRP-2 Silencer Select siRNA ID:S16840) or Negative
Control (Negative Control #1 Silencer Select siRNA) at a
final concentration of 5 nM, also using Lipofectamine 2000
(Invitrogen). Cells were harvested after 48 h for protein
extraction.
Reporter gene assays were performed as described [16].
GBM cells were seeded in 12-well plates and transfected
with 100 ng of firefly luciferase reporter plasmid DNA
(NRP-2 or Negative control; Gencopoeia) and miRNA
precursor (Ambion; pre-miR-331-3p or pre-miR-NC;
1–5 nM final concentration), using Lipofectamine 2000.
After 24 h, lysates were assayed for firefly and Renilla
luciferase activities using the dual luciferase reporter assay
system (Promega) and a Fluostar OPTIMA microplate
reader (BMG Labtech). Firefly luciferase activity for each
sample was normalized to Renilla luciferase activity to
yield a relative luciferase activity.
Protein extraction and western blotting
Cytoplasmic protein extracts were prepared and western
blotting performed as described [16]. Briefly, protein
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samples were resolved on NuPAGE 4–12 % Bis Tris gels
(Invitrogen) and transferred to PVDF membranes (Roche).
Membranes were blocked in 5 % skim milk/TBST and
probed with either anti-tubulin rat polyclonal antibody
(1:1,000, Abcam ab6161-100), anti-b-actin mouse mono-
clonal antibody (1:10,000, Abcam ab6276-100), anti NRP-
2 (C-9) mouse polyclonal antibody (Santa Cruz Biotech-
nology sc-13117) or anti-DOHH (C-19) goat polyclonal
antibody (1:1,000, Santa Cruz Biotechnology sc-55157).
Detection was performed with horseradish peroxidise-
linked anti-rat-IgG (1:10,000; ab6734-1; Abcam), anti-
mouse-IgG (1:10,000; NA931 V; GE Healthcare) and
anti-sheep/goat-IgG (1:10,000; AB324P; Chemicon) sec-
ondary antibodies with ECL Plus detection reagent and
ECL-Hyperfilm (GE Healthcare).
Clonogenicity, cell proliferation and migration assays
Clonogenicity assays were performed using U-251 MG and
U-373 MG cells transiently transfected with miR-NC or
miR-331-3p as described previously [17]. For cell titre
assays, GBM cells were transfected with miRNA precursor
molecules (see above) and cell proliferation was assessed
at 7 days post transfection with the CellTiter 96 Aqueous
One Solution Cell Proliferation System (Promega) and a
Fluostar Optima plate reader (BMG Scientific). The
xCELLigence real time proliferation system (Roche) was
used to detect changes in proliferation of GBM cells over a
120 h period in real time. Briefly, GBM cells were trans-
fected with miRNA precursor molecules and trypsinized
and counted after 48 h. E-plate16 xCELLigence plates
were prepared as per manufacturer’s recommendations and
transfected GBM cells added to wells in groups of 4 wells
per treatment. Cell proliferation was measured by a cal-
culated cell index using the xCELLigence device. At the
completion of the experiment, cell proliferation curves
were normalised at 10 h post seeding (where true t = 0
was at t = 10 h; see Fig. 3b) of cells in the E-plate16 to the
miR-NC transfected cells, to achieve the same base line
cell index for both miR-NC and miR-331-3p transfected
GBM cells in the assay. Migration of transfected U-251
MG cells in the CIM-plate16 was monitored with an
xCELLigence real time migration system (Roche) as
described previously ([18]).
Statistical and scatterplot analyses
Statistical analysis of RT-qPCR data was performed using
GENEX software (MultiD). All analyses were performed
at a minimum confidence interval of 95 % (CI 0.95) and
normality of data confirmed by Kolmogorov-Smirnoff test
(KS Test). Statistical analysis of reporter gene assay data
was performed using Student’s t test, where p \ 0.05
represented a significant difference. Error bars represent
standard deviations (SD).
































































Fig. 1 miR-331-3p is down regulated in GBM cell lines compared to
normal brain and inhibits cell proliferation and clonogenicity.
a TaqMan RT-qPCR analysis of miR-331-3p expression in U-87
MG and U-251 MG cells relative to normal brain RNA. b Cell titre
assay of U-251 MG cell proliferation following transient transfection
with either miR-331-3p or negative control miRNA (miR-NC).
c Clonogenicity assay of U-251 MG cells 12 days following transient
transfection with either miR-331-3p or miR-NC. Error bars represent
standard deviations; *p \ 0.05, **p \ 0.01
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To investigate the relationship between the expression
of miR-331-3p and NRP-2 in human GBM and normal
brain tissue, we utilized data from TCGA [19]. We queried
the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/,
accessed March 2013) for all GBM and normal brain tissue
samples with Level 3 miRNA (Agilent 8 9 15 K Human
miRNA-specific Microarray) and gene (Affymetrix HT
Human Genome U133 Array Plate Set) expression data
available. The resulting data set was filtered for samples
having expression data for both miR-331-3p and NRP-2,
yielding a final set of 491 independent patient samples,
including 482 GBM and 9 unmatched normal brain sam-
ples. Statistical analyses were performed using the statis-
tical analysis package, R [20]. A simple linear model was
fit to the miR-331-3p and NRP-2 expression data using the
lm function.
Results
miR-331-3p expression in GBM cell lines is
significantly lower than in normal brain and miR-331-
3p inhibits proliferation and clonogenic growth
of GBM cell lines
Previously, we demonstrated a tumor suppressor role for
miR-331-3p in prostate cancer, where miR-331-3p expres-
sion is reduced in a cohort of patient tumors relative to
matched normal adjacent tissue [12, 14]. Following a report
by Gaur and co-workers [6] which demonstrated that miR-
331-3p expression is decreased in a panel of CNS tumor cell
lines (SNB19, SF295, SF539, U-251 MG, SF268, SNB75)
relative to normal brain tissue, we used TaqMan miRNA RT-
qPCR assays to determine miR-331-3p levels in U-87 MG
and U-251 MG GBM cell lines compared with normal brain
RNA. Our data are consistent with the above-mentioned
report and show that miR-331-3p expression is significantly
lower in both GBM cell lines relative to normal brain
(Fig. 1a), suggesting that it may have a tumor suppressor role
in this system.
To investigate the functional significance of miR-331-3p
loss in GBM, we transiently transfected U-251 MG and
U-373 MG cells with either a synthetic miR-331-3p mimic
or a negative control miRNA mimic (miR-NC), and mea-
sured cell viability over time as a measure of cell prolif-
eration. Our data indicate that miR-331-3p transfection
reduced cell proliferation over a 7 day period (Fig. 1b for
U-251 MG, and data not shown for U-373 MG cells). To
support this finding, we assessed the clonogenic growth of
U-251 MG cells transfected with either miR-331-3p or
miR-NC, and found that transfection of miR-331-3p sup-
pressed colony formation over a 3 week period (Fig. 1c).
Taken together, our results suggest that down regulation of
miR-331-3p may promote the growth of GBM cells.
Neuropilin-2 (NRP-2) is targeted by miR-331-3p
in GBM cell lines
To assess the tumor suppressive action of miR-331-3p in
GBM cells, we used miRNA target prediction software
(TargetScan Release 6.2, June 2012) [21] to identify
putative miR-331-3p target mRNAs that could mediate its
anti-proliferative effects in GBM. Using a similar approach
we previously identified ErbB-2 and Deoxyhypusine
hydroxylase (DOHH) as novel targets of miR-331-3p in
prostate cancer [12, 14]. TargetScan analysis indicated that
the second highest confidence predicted target of miR-331-
3p is NRP-2.
Analysis of the 30-untranslated region (30-UTR) of NRP-
2 revealed six putative miR-331-3p target sites (Fig. 2a and
Table 1), one of which is conserved across species. To
determine whether miR-331-3p could target the NRP-2
30-UTR, we co-transfected U-251 MG and U-373 MG cells
with a luciferase reporter construct containing the full
length NRP-2 30-UTR and either miR-331-3p or miR-NC.
We observed that miR-331-3p significantly decreased
reporter gene activity relative to miR-NC (Fig. 2b), indi-
cating that the NRP-2 30-UTR contains functional target
sites for binding and activity of miR-331-3p. Furthermore,
transfection of U-251 MG, U-87 MG and U-373 MG cells
with miR-331-3p inhibited expression of endogenous NRP-
2 protein by western blotting (Fig. 2c). As a positive
control for this assay we assessed the expression of DOHH,
a validated miR-331-3p target in prostate cancer cells [14]
and found that DOHH expression was decreased in GBM
cells following transfection of miR-331-3p (data not
shown). Together, our results indicate that miR-331-3p is a
potent regulator of NRP-2 expression in GBM cells.
NRP-2 regulates proliferation and clonogenic growth
of GBM cell lines
To validate NRP-2 as a functional target of miR-331-3p in
GBM, we used RNAi to inhibit NRP-2 expression in U-251
MG and U-373 MG cells. We first confirmed that NRP-2
RNAi decreased NRP-2 expression by western blotting
relative to negative control siRNA (Fig. 3a). As a control
for this experiment, we also transfected U-251 MG and
U-373 MG cells with either miR-331-3p or miR-NC and
observed reduced NRP-2 expression with miR-331-3p
(Fig. 3a). We next assessed the impact of NRP-2 RNAi on
the proliferation and clonogenic growth of U-251 MG and
U-373 MG cells. Using a real-time xCELLigence assay,
transfection of each cell line with NRP-2 siRNA (si-NRP-
2) significantly inhibited proliferation over a 120 h period
70 J Neurooncol (2014) 116:67–75
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relative to non-targeting siRNA (si-NC) (Fig. 3b). In
addition, NRP-2 siRNA transfectants exhibited reduced
colony formation over a 14 day period (Fig. 3c). The
similarity in effects on proliferation and clonogenicity
between NRP-2 RNAi and miR-331-3p transfection
(Fig. 1) suggest that NRP-2 may be a key functional target
of miR-331-3p in GBM.
Inhibition of NRP-2 by miR-331-3p or NRP-2 siRNA
represses the migration of U-251 MG GBM cells
As NRP-2 is known to promote GBM cell motility [22], we
tested the capacity for miR-331-3p to regulate migration of
U-251 MG cells in vitro using xCELLIGENCE real-time
migration assays. Transfection with either miR-331-3p or
NRP-2 siRNA significantly repressed migration of U-251
MG cells (Fig. 4a, b), and suggested that the anti-migratory
effect of miR-331-3p is at least in part mediated by its
repression of NRP-2 expression.
NRP-2 expression is inversely correlated with miR-
331-3p expression in a GBM patient cohort
The expression of miR-331-3p and NRP-2 in GBM and
normal brain tissue samples from TCGA was visualized
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Fig. 2 NRP-2 expression is regulated by miR-331-3p in GBM cells.
a Schematic representation of the NRP-2 mRNA, showing the
30-UTR containing six predicted miR-331-3p binding sites (TargetScan
version 6.2, June 2012). Nucleotide positions of miR-331-3p seed
sequence sites are shown within the 30-UTR, with boxes shaded light
for non-conserved sites and dark for conserved sites. b Luciferase
reporter assay using U-251 MG and U-373 MG cells co-transfected
with full length NRP-2 30-UTR luciferase reporter gene plasmid DNA
and either miR-331-3p or miR-NC. For each sample, firefly luciferase
activity was normalized to Renilla luciferase activity, and data is
expressed relative to each cell line cotransfected with reporter
plasmid DNA and miR-NC. Data for each reporter construct is
expressed relative to miR-NC transfected cells. Error bars represent
standard deviations; *p \ 0.05. c Western blotting analysis of NRP-2
protein expression in U-251 MG, U-87 MG and U-373 MG GBM
cells 48 h after miR-331-3p or miR-NC transfection. a-tubulin is
included as a loading control
Table 1 miR-331-3p seed regions and their respective TargetScan
context scores within the NRP-2 30-UTR






Position 177–183 46 Poorly conserved
Position 645–652 97 Conserved
Position 979–985 29 Poorly conserved
Position 2,318–2,324 57 Poorly conserved
Position 2,602–2,609 91 Poorly conserved
Position 2802–2808 43 Poorly conserved
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indicates a significant inverse relationship between miR-
331-3p and NRP-2 expression (p = 1.5 9 10-7), with a
correlation coefficient of r = -0.23 (r2 = 0.055). All
normal brain samples had miR-331-3p expression values
above the 93rd percentile of the GBM samples, with only
34 of 482 GBM samples (7 %) having values in the same
range. NRP-2 expression values in normal brain samples
were all below the 54th percentile of the GBM samples
with 260 of 482 GBM samples (54 %) having values in this
range. Only 24 of 482 GBM samples (5 %) had both miR-
331-3p and NRP-2 expression in the same range as the
normal brain samples.
Discussion
In this study we have investigated the significance of miR-
331-3p regulation of NRP-2 in GBM. We found several
lines of evidence to suggest that miR-331-3p is a tumor
suppressor miRNA in GBM. Firstly, we identified low
miR-331-3p expression in GBM cell lines compared to
normal brain. Secondly, transfection of miR-331-3p
decreased proliferation and clonogenic growth of GBM
cell lines. Our results provide evidence that NRP-2 is a
target of miR-331-3p, and we show that inhibition of NRP-














































































Fig. 3 NRP-2 promotes GBM cell proliferation and clonogenicity.
a Western blotting analysis of NRP-2 and DOHH protein expression
in U-251 MG and U-373 MG GBM cells 48 h after transfection with
miR-331-3p, miR-NC, si-NRP-2, or si-NC (negative control siRNA).
DOHH was included as a positive control (known miR-331-3p target),
and b-actin was included as a loading control. b xCELLigence assay
of U-251 MG and U-373 MG cell proliferation in real time following
transient transfection with either si-NRP-2 or si-NC. Data was
normalized to measured cell index at 10 h post-seeding of cells in
xCELLigence plates. c Clonogenicity assay of U-373 MG and U-251
MG cells following transient transfection with either si-NRP-2 or si-
NC. Colonies were fixed with ice-cold methanol and stained with
crystal violet 12 days after plating of cells. Error bars represent
standard deviations; *p \ 0.05
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clonogenicity. Furthermore, miR-331-3p inhibits GBM cell
migration, an effect that can in part be attributed to its
suppression of NRP-2 expression. Finally, analysis of 491
GBM and normal brain tissue samples from TCGA sup-
ported an inverse relationship between miR-331-3p and
NRP-2 expression, consistent with NRP-2 being a target of
miR-331-3p.
A number of tumor suppressor miRNAs have been
identified as being downregulated in GBM; including
miR-7, miR-34a, miR-128, and miR-137 (reviewed in
[23]). In addition to demonstrating reduced expression of
miR-331-3p in GBM cell lines and patient tumors, we
previously found that miR-331-3p expression is reduced in
prostate cancer tissue relative to matched normal adjacent
tissue [12, 14]. The human miR-331 gene is located at
12q22, a chromosomal region that is frequently lost in
GBM [24]. It would be interesting to correlate expression
of the miR-331-3p primary transcript with 12q22 loss in
GBM. We and others identified several targets of miR-331-
3p in prostate cancer cells, including ErbB-2 [12], DOHH
[14] and KLK4 [25]. It was also proposed that miR-331-3p
may coordinately regulate cell cycle progression in gastric
cancer cells [26]. Interestingly, in the present study we
observed that expression of DOHH, an enzyme involved in
the activation of eIF5A and control of cell cycle progres-
sion [27], is regulated by miR-331-3p in GBM cell lines. A
recent report by Preukschas and coworkers showed that
DOHH is highly overexpressed in GBM patient tissues, and
that inhibition of DOHH action in GBM cell lines caused
cell cycle arrest and sensitized cells to clinically relevant
alkylating agents [28]. Taken together, these findings
suggest that miR-331-3p acts as a tumor suppressor in the
brain by coordinately inhibiting expression of multiple
target molecules, including NRP-2 and DOHH, leading to
reduced GBM cell proliferation and clonogenic growth.
The capacity for miR-331-3p to regulate NRP-2
expression is of interest given a number of recent reports
that emphasize the importance of NRP-2 in tumor growth
and progression, and as a promising therapeutic target.
CNS tumors (e.g. neuroblastoma) frequently express NRP-
2 [29], and NRP-2 expression is also elevated in high-grade




















































Fig. 4 Reduced migration of U-251 MG cells following transfection
with miR-331-3p or siRNA to NRP-2. xCELLigence assay of U-251
MG cell migration in real time following transient transfection with
either a miR-331-3p or b si-NRP-2. Data is expressed relative to miR-




















Fig. 5 Inverse association between expression of miR-331-3p and
NRP-2 in The Cancer Genome Atlas (TCGA) GBM cohort.
Scatterplot of miR-331-3p and NRP-2 expression in GBM (unfilled
circles) and unmatched normal brain (red-filled circles) tissue
samples from TCGA with fitted regression line (red line). The 93rd
percentile of miR-331-3p expression in the GBM samples (vertical
black line) and 54th percentile of NRP-2 expression in the GBM
samples (horizontal black line) delineate the range of expression
values of the normal brain samples (shaded grey area). Scale
indicates NRP-2 (vertical) and miR-331-3p (horizontal) probe
intensities
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glioblastoma [31]. NRP-2 is essential for breast cancer
tumor initiation [32], where it is involved in the formation
of focal adhesions [33] and is associated with metastasis
and poor prognosis [34]. NRP-2 also promotes the invasion
and migration of thyroid cancer cells in vitro, an effect that
could be blocked by a neutralizing anti-NRP-2 antibody
[35]. Furthermore, combined blockade of NRP-2 action
and treatment with bevacizumab anti-angiogenic therapy
produced synergistic inhibition of melanoma xenograft
growth [36], a finding that has implications for GBM
treatment given the emerging therapeutic role of bev-
acizumab in this disease [37]. Treatment of mice with
NRP-2 siRNA inhibited the growth of colorectal cancer
hepatic metastases, providing proof-of-principle for treat-
ment with small RNA molecules against NRP-2 [38]. It
would be of interest to evaluate the anti-tumor efficacy of
systemic or local miR-331-3p delivery, particularly given
the apparent feasibility of miRNA-based therapies in var-
ious CNS tumor types [3].
In summary, we have identified miR-331-3p as a novel
regulator of NRP-2 in GBM. Elevated NRP-2 expression is
correlated with low levels of miR-331-3p in clinical GBM
samples. miR-331-3p acts at least in part via blocking
NRP-2 to inhibit GBM cell proliferation, clonogenic
growth, and migration. These results warrant further
investigation into both the functional roles and the thera-
peutic and prognostic utility of these molecules in GBM.
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